PTC Therapeutics, Inc.
PTCT
Rank in Stocks
#3377
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the... PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
Share Price
$61.65
Last synced: 2026-10-19
Market Cap
$5.15B
Change (1 day)
4.07%
Change (1 year)
-9.82%
Country
US
Trade PTC Therapeutics, Inc. (PTCT)
Category
Healthcare
Revenue for PTC Therapeutics, Inc. (PTCT)
Revenue in Jun 2026 TTM: $1.01B
According to PTC Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is $1.01B. In 2023 the company made a revenue of $937.82M an increase over the revenue in the year 2022 that was $698.80M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for PTC Therapeutics, Inc. from 2011 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $1.01B | 25.03% |
| 2024 | $806.78M | -13.97% |
| 2023 | $937.82M | 34.20% |
| 2022 | $698.80M | 29.75% |
| 2021 | $538.59M | 41.45% |
| 2020 | $380.77M | 24.04% |
| 2019 | $306.98M | 15.96% |
| 2018 | $264.73M | 36.19% |
| 2017 | $194.39M | 135.04% |
| 2016 | $82.71M | 124.95% |
| 2015 | $36.77M | 60.11% |
| 2014 | $22.96M | -26.70% |
| 2013 | $31.33M | 8.85% |
| 2012 | $28.78M | -70.92% |
| 2011 | $98.96M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 1,151.47% |
US
|
|
| $2.23B | 120.87% |
US
|
|
| $15.74B | 1,460.77% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 496.90% |
NL
|
